Viva Biotech Holdings (HKSE:01873) COGS-to-Revenue : 0.65 (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Viva Biotech Holdings COGS-to-Revenue?

Viva Biotech Holdings's Cost of Goods Sold for the six months ended in Dec. 2024 was HK$701 Mil. Its Revenue for the six months ended in Dec. 2024 was HK$1,073 Mil.

Viva Biotech Holdings's COGS to Revenue for the six months ended in Dec. 2024 was 0.65.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Viva Biotech Holdings's Gross Margin % for the six months ended in Dec. 2024 was 34.66%.

Viva Biotech Holdings COGS-to-Revenue Historical Data

The historical data trend for Viva Biotech Holdings's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viva Biotech Holdings COGS-to-Revenue Chart

Viva Biotech Holdings Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

COGS-to-Revenue

Get a 7-Day Free Trial

0.56

0.69

0.66

0.65

Viva Biotech Holdings Semi-Annual Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
COGS-to-Revenue	Get a 7-Day Free Trial											0.63	0.64	0.67	0.65	0.65

Viva Biotech Holdings COGS-to-Revenue Calculation

Viva Biotech Holdings's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	1387.175	/	2121.092
	=	0.65

Viva Biotech Holdings's COGS to Revenue for the quarter that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	701.005	/	1072.826
	=	0.65

Viva Biotech Holdings (HKSE:01873) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Viva Biotech Holdings's Gross Margin % for the six months ended in Dec. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	701.005 / 1072.826
	=	34.66 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Viva Biotech Holdings COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Viva Biotech Holdings's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Viva Biotech Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viva Biotech Holdings (HKSE:01873) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

VBIZF:USA VB0:Germany

Address

735 Ziping Road, Pudong New District, Zhoupu Town, Shanghai, CHN, 201318

Website

https://www.vivabiotech.com

Viva Biotech Holdings is engaged in providing the structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development. The company operates in three reportable segments, Drug Discovery Services providing structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development; Contract Development Manufacture Organisation providing contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations; and commercialisation services; and Viva BioInnovator making strategic investments in biotechnology startup companies.

Executives

Mao Chen Cheney	2101 Beneficial owner
Temasek Holdings (private) Limited	2201 Interest of corporation controlled by you
Mao Jun	2501 Other
Wu John Jiong	2201 Interest of corporation controlled by you
Fenghe Harvest Ltd	2101 Beneficial owner
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Zhou Min	2202 Interest of your spouse
Intertrust (singapore) Ltd.	2301 Trustee
Z&m International Holdings Limited	2201 Interest of corporation controlled by you
Zhang And Sons Limited	2101 Beneficial owner

Viva Biotech Holdings Headlines

No Headlines